Abstract. An important role for CX 3 CL1 in neuroinflammation and neurodegeneration has been suggested in recent publications. In this study, we compared the expression of CX 3 CL1 and its receptor CX 3 CR1 in human brain tissue derived from control patients without neurological complications and in multiple sclerosis (MS) patients. Results from this study demonstrate that CX 3 CL1 is constitutively expressed in human central nervous system (CNS) astrocytes in vivo and under basal conditions in human adult astrocyte cultures. CX 3 CR1 is expressed on astrocytes and microglial cells both in vivo and in vitro. Chemotaxis assay shows a functional response upon CX 3 CR1 signaling in microglial cells. Although CX 3 CL1 expression is upregulated in cultured astrocytes in response to proinflammatory cytokines, no evidence for expression differences of CX 3 CL1 between control patients and MS patients was found. Our data suggest that CX 3 CL1 has more general physiological functions, which occur also in the absence of proinflammatory conditions.
INTRODUCTION
Chemokines represent a superfamily of proteins involved in directed cell movement. They play a major role in the peripheral immune system and are known to be involved in inflammation that occurs in neurodegenerative diseases such as Alzheimer disease or multiple sclerosis (MS) (1, 2) . Chemokines have been divided, based on their structure, into 4 different subfamilies classified as C (␥), CC (␤), CXC (␣), and CX 3 C (␦).
Chemokines and/or their receptors, which are present at low levels in normal brain, are mostly upregulated during inflammatory processes in the central nervous system (CNS). The expression of chemokines in the brain is most likely controlled by inflammatory mediators that are present in neurodegenerative diseases. Accordingly, in tissue culture, ␣-and ␤-chemokines are induced by distinct sets of stimuli in inflammatory cells and endogenous CNS glial cells (3) (4) (5) (6) (7) . CX 3 CL1 (fractalkine) is the only member of the ␦-chemokine subfamily. CX 3 CL1 has distinct structural features compared to other chemokines, including a CX 3 C motif in the N-terminus, a glycosylated mucin-like stalk that binds the chemokine domain to a transmembrane spanning domain, and short intracellular domains (8, 9) . The physiological roles of CX 3 CL1 are only beginning to be understood. The membrane-anchored localization of CX 3 CL1 has led to the suggestion that it functions as a cell adhesion molecule for circulating inflammatory cells (10, 11) . In addition, CX 3 CL1 can be cleaved from the cell membrane to produce a soluble form that creates a chemotaxic gradient for receptive inflammatory cells. Both the adhesion and chemotactic properties of CX 3 CL1 are mediated via a specific G-protein coupled 7 transmembrane domain receptor (CX 3 CR1) (12, 13) . CX 3 CL1 is almost exclusively expressed in the brain as has been shown by distribution studies in rodent and human (9, (14) (15) (16) . There is some debate concerning expression studies; CX 3 CL1 was principally shown to be expressed in neurons and endothelial cells (8, (14) (15) (16) (17) (18) (19) . However, more recently astrocytes have also been shown to express CX 3 CL1 (15, 17, 18, 20, 21) . CX 3 CR1 is expressed on leukocytes, microglia, neurons, and astrocytes (14, 15, (17) (18) (19) (20) 22) .
The biological role of CX 3 CL1 and CX 3 CR1 in the brain is still an ambiguity. CX 3 CL1 mRNA expression in neurons is not upregulated by inflammatory cytokines, growth factors, or noxious stimuli, suggesting a role in homeostasis and ontogeny (14, 16, 18) . In contrast, CX 3 CL1 expression by astrocytes is upregulated by TNF␣ and IL-1␤ (18) . Furthermore, upregulation of CX 3 CL1 has been reported during experimental immune encephalomyelitis, facial motor nerve axotomy, and HIV-1 encephalitis (9, 14, 19, 21) . Only recently, Hughes et al examined the cellular distribution and expression of CX 3 CL1 and CX 3 CR1 during chronic and acute inflammation in rodent CNS (20) . In that study, it was suggested that the surrounding cytokine environment during inflammation may influence the changes in glial expression of both CX 3 CL1 and CX 3 CR1. A detailed study on CX 3 CL1 and CX 3 CR1 expression in human brain tissue and in MS lesions has not yet been performed. We therefore studied the expression of CX 3 CL1 and CX 3 CR1 both in vivo and in vitro in brain samples derived from patients without neurological complications as well as from multiple sclerosis patients, and performed functional studies on CX 3 CR1 signaling in human adult microglial cells.
MATERIALS AND METHODS

Human Brain Tissue
Human brain tissue was obtained by rapid autopsy according to standardized procedures under the management of the Netherlands Brain Bank (Amsterdam, The Netherlands). All patients or their next of kin had given written consent for autopsy and use of their brain tissue for research purposes. Medical records were obtained for all patients prior to autopsy and pathological evaluation was performed to confirm the clinical diagnosis. Brain samples were obtained from 15 patients without neurological complications (exclusion of patients with white matter pathology or inflammatory processes) and 23 patients with multiple sclerosis. For further details see the Table. Brain tissue samples for culturing were taken from the subcortical white matter or corpus callosum and were collected in Dulbecco's modification of Eagle's medium (DMEM) with 4,500 mg/l glucose and pyridoxine HCl (Gibco BRL Life Technologies, Breda, The Netherlands) diluted 1:1 with Nutrient mixture F10 (HAMF10, Gibco) with L-glutamine (Gibco), and supplemented with 50 g/ml gentamicin (Gibco).
For immunohistochemical analyses, samples were taken from the subcortical white matter and cortical gray matter. In all MS cases, additional tissue samples were taken from lesions located in the brain. In most cases, samples were taken from areas around the ventricles and subcortical white matter. The sampling of the MS patients was done using a magnetic resonance imaging (MRI)-guided protocol (23) . Tissue samples were snap-frozen and stored in liquid nitrogen. The different lesional stages in the collected material were determined on the basis of immunological parameters, including the presence of inflammatory cells (CD45-positive lymphocytes/macrophages and CD68-positive macrophages containing phagocytized myelin components), enhanced expression of major histocompatibility complex class II antigen and CD45 antigen on leukocytes and resident microglial cells, the intensity of astrogliosis, as well as certain morphological criteria such as cellularity of the center and rim of the lesion (23) .
Human Adult Astrocyte and Microglia Cell Cultures
Isolation of human adult astrocytes and microglia was performed as described previously (24) . Brain tissue samples were dissected from various regions of the brain derived from normal control cases and collected in DMEM/HAMF10 (Gibco BRL Life Technologies). Independent cell cultures were established from each single sample derived from a specific brain region. The tissue samples were minced into small fragments (Ͻ2 mm 3 ) and digested with a 0.25% trypsin solution (Sigma, St. Louis, MO) containing 0.05% DNase (Boehringer, Mannheim, Germany). For the isolation of astrocytes, after digestion the cell suspension was gently triturated and diluted with culture medium (DMEM/HAMF10 containing 10% (v/v) fetal bovine serum (FBS, heat inactivated; Integro, Zaandam, The Netherlands), 2 mM L-glutamine, 100 IU/ml penicillin and 50 g/ml streptomycin-sulphate). The astrocytes were cultured in poly-Llysine coated 80 cm 2 -culture flasks in culture medium at approximately 0.5 g wet weight tissue/10 ml medium. Flasks were incubated at 37 o C in a humidified atmosphere of 5% CO 2 and 95% air for 48 h, after which the culture medium was changed to remove unattached cells and myelin debris. Subsequently, the medium was changed once a week with fresh medium and oligoclonal astrocyte cultures were grown to reach confluency. The human astrocyte cultures were immunoreactive (Ͼ95%) for GFAP and glutamine synthetase, and did not stain with monoclonal antibodies LeuM5 (CD11c) and LeuM3 (CD14) (Becton Dickinson, Erembodegem, Belgium), indicating that contamination with macrophage/microglial cells was negligible (Ͻ1%). For microglia cell cultures, after digestion the cells were passed through a nylon mesh filter (Falcon) and centrifuged. Thereafter, the cell pellet was taken up in a percoll/myelin-gradient buffer and again centrifuged to remove cell debris/myelin. For lysis of erythrocytes, the cell pellet was resuspended with a NH 4 CL (0.155 M) and KHCO 3 ml medium. Flasks were incubated at 37 o C in a humidified atmosphere of 5% CO 2 and 95% air. Microglial cells adhered to the bottom of the culture flask within 12 hours. To induce proliferation of microglial cells, recombinant human granulocytemacrophage colony stimulating factor (rhGM-CSF; leucomax, Novartis Pharma B.V., Arnhem, The Netherlands) was added (final concentration 25 ng/ml) to the adherent cell cultures every 3 days. The culture medium was changed once a week using fresh culture medium. In addition, more than 98% of the cultured microglial cells are immunoreactive for CD68, LeuM5, LeuM3, CR3/43 (HLA-DR/DQ/DP) and CD45, indicating that contamination is negligible.
Stimulation Experiments
For stimulation, astrocytes cultures grown in 80 cm 2 flasks were trypsinized and seeded into 25 cm 2 flasks at a density of 1 ϫ 10 5 astrocytes per flask in culture medium. After settling for 5 days, medium was replaced by DMEM/HAM-F10 containing 0.1% (v/v) FBS to reduce proliferation. Microglial cells were stimulated in the original 80-cm 2 flasks. One week after isolation, medium of microglial cells was replaced by DMEM/ HAM-F10 containing 0.1% (v/v) FBS. A dose of 625 U/ml recombinant human TNF␣, 400 U/ml recombinant human IFN␥, 200 U/ml recombinant human IL-1␤, 1 g/ml LPS, 10 ng/ml recombinant human IL-4, IL-10 or TGF␤1 was added and cells were incubated for 6 hours.
Reverse Transcription-Polymerase Chain Reaction
Cells were lysed in guanidinium isothiocyanate/mercaptoethanol buffer and total RNA was extracted according to Chomczynski and Sacchi (25) . Reverse transcription (RT): 1 g and 0.5 g of total RNA from astrocytes and microglia respectively was transcribed into cDNA in a final volume of 25 l containing 1 l of M-MLV RT (Promega, Leiden, The Netherlands), 0.5 l of RNase inhibitor (Promega), 1 l of random hexamers (2.5 nM), 3.5 l H 2 O, 5 l 5x M-MLV RT Buffer (Promega), and 5 l deoxynucleosidetriphosphates (dNTPs, 2 mM). After 10 min of incubation at 25ЊC and 60 min at 42ЊC, the reaction was stopped by heating at 95ЊC for 5 min. The quality of the cDNA was controlled using glyceralderhyde-3-phosphate dehydrogenase (GAPDH) primers and potential contamination by genomic DNA was checked for by running the reactions without reverse transcriptase and using GAPDH primers in subsequent polymerase chain reaction (PCR) amplifications. PCR: 1 l of the RT reaction was used in a 50 l PCR amplification containing 5 l 10 ϫ PCR buffer (100 mM Tris pH 8.3, 500 mM KCl, 15 mM MgCl 2 ), 5 l of 2 mM dNTPs, 1 l of each primer, and 0.5 l Taq polymerase (Perkin Elmer, Zaventem, Belgium). Sequences of oligonucleotide primer pairs and PCR conditions were as follows. CX 3 CL1: forward primer 5Ј-GGT GTGACGAAATGCAACAT-3Ј; backward primer 5Ј-GCTTCC TGGGAAGAAGGAGT-3Ј, annealing temperature 56ЊC for 35 cycles. GAPDH: forward primer 5Ј-CATCCTGCACCACCA ACTGCTTAG-3Ј; backward primer 5Ј-GCCTGCTTCACCACC TTCTTGATG-3Ј, annealing temperature 60ЊC for 27 cycles.
Immunohistochemistry
Serial 5-m-thick cryostat sections of MS lesions and control tissue were collected onto Superfrost glass slides (Menzel-Glä-ser, Braunscheig, Germany) and dried overnight at room temperature. The sections were fixed with paraformaldehyde for 10 min. All washes were carried out for 30 min with phosphatebuffered saline (PBS, 0.01 M, pH 7.4) and antibodies were diluted in PBS containing 1% BSA. Sections were immunostained by the streptavidin-biotin complex (sABC) procedure, previously described in detail (24) . Sections were preincubated with 10% normal swine serum for 10 min. The rabbit antihuman CX 3 CL1 (gift from T. Schall [8] ) and CX 3 CR1 (Torrey Pines Biolabs, Houston, TX) antibodies were diluted 1:100 and 1:500, respectively, and incubated overnight at 4ЊC. Slides were incubated with a biotinylated swine anti-rabbit IgG F(abЈ) 2 (1: 300, DAKO, Copenhagen, Denmark) for 30 min at room temperature followed by additional washing steps. HRP-linked sABC (sABC-HRP: DAKO) was used for 1 h at room temperature, and peroxidase activity was demonstrated with 0.5 mg/ ml 3,3Ј-diaminobenzidine tetrahydrochloride (DAB: Sigma) in PBS containing 0.03% H 2 O 2 for 5 min. Negative controls were set up omitting the primary antibody. Irrelevant polyclonal antibodies were also included to confirm the specificity of the CX 3 CL1 and CX 3 CR1 staining patterns. All sections were evaluated by light microscopy by at least 2 independent observers.
Immunocytochemistry
Cells were rinsed with PBS, incubated for 2 min (astrocytes) or 10 min (microglia) with 0.25% w/v porcine trypsin at 37ЊC, washed once with culture medium, and replated into 24-well plates at a density of 1 ϫ 10 4 cells /ml per well in culture medium. After 3 days, astrocytes and microglia were immunocytochemically stained. Cells were fixed with methanol for 10 min atϪ20ЊC. All washes were carried out for 30 min with PBS containing 0.1% BSA and 0.05% saponin. Antibodies were diluted in PBS containing 1% BSA and 0.05% saponin. Astrocytes and microglia were immunostained using EnVision-HRP (DAKO). , and incubated overnight at 4ЊC, followed by washing. Slides were incubated with EnVision-HRP for 30 min at room temperature followed by additional washing. Peroxidase activity was demonstrated with 3-amino-9-ethylcarbazole (Zymed Laboratories, Inc., Uden, The Netherlands). Negative controls were set up omitting the primary antibodies. Irrelevant polyclonal antibodies were also included to confirm the specificity of the used CX 3 CL1 and CX 3 CR1 antibodies.
Chemotaxis Assay
Microglial cell migration in response to CX 3 CL1 was assessed using a 48-well chemotaxis microchamber (Neuroprobe, Bethesda, MD) as described earlier (26) . Chemokine stock solutions (10 M) were prepared in PBS and further diluted in serum-free culture medium for use in the assay. Culture medium without CX 3 CL1 served as a control and 1.5 ϫ 10 4 cells per 50 l were used for microglia. Determinations were done in quadruplicate. The chamber was incubated at 37ЊC, 5% CO 2 in a humidified atmosphere for 120 min. At the end of the incubation the filter was washed, fixed in methanol, and stained with toluidine blue. Migrated cells were counted with a scored eyepiece (3 fields 
RESULTS
CX 3 CL1 and CX 3 CR1 Protein Expression in Control and MS Brain Tissue
CX 3 CL1 and CX 3 CR1 immunoreactivity and cellular localization was determined by immunohistochemistry on tissue sections from control patients without neurological complications and MS patients. In normal subcortical white matter derived from control cases and in normal appearing white matter (NAWM) surrounding demyelinated MS lesions, strong immunoreactivity to CX 3 CL1 was observed in astrocytes with long processes (Fig. 1A, B) . Also, moderate immunoreactivity to CX 3 CL1 was observed on endothelial cells (Fig. 1B) tissues from normal control and MS patients. In macrophages that are present in active lesions and the hypercellular rim of chronic active lesions, a weak immunoreactivity to CX 3 CL1 was detected (Fig. 1C) . Moreover, neurons in the cortical gray matter were immunopositive for CX 3 CL1 (Fig. 1D) . Microglia displayed no immunoreactivity to CX 3 CL1.
Strong CX 3 CR1 immunoreactivity was observed in astrocytes in subcortical white matter from control patients and NAWM (Fig. 1E) in MS brain samples without a distinct intensity difference between these samples. Moreover, macrophages present in active demyelinating and chronic active MS lesions showed a marked staining for CX 3 CR1 (Fig. 1F) . Microglia in subcortical white matter from control patients, NAWM, and preactive lesions in MS brain samples showed a weak immunoreactivity to CX 3 CR1 (Fig. 1G) . Furthermore, neurons in the cortical gray matter from both control patients and MS patients showed a weak to moderate immunoreactivity to CX 3 CR1 depending on the tissue sample observed (not shown). Using irrelevant polyclonal antibodies or omitting the primary antibody resulted in the absence of immunoreactivity, thereby confirming the specificity of the CX 3 CL1 and CX 3 CR1 staining patterns.
Expression of CX 3 CL1 and CX 3 CR1 in Cultured Human Adult Astrocytes and Microglial Cells
Immunocytochemical staining for CX 3 CL1 and CX 3 CR1 was performed on methanol-fixed cultures of human adult astrocytes and microglia isolated from MS patients and patients without neurological complications. Astrocytes displayed a strong immunoreactivity for GFAP ( Fig. 2A) and vimentin. In addition, strong immunoreactivity for CX 3 CL1 was detected in cultured astrocytes (Fig. 2B) . Human adult microglial cells showed an intense immunoreactivity for CD68 (Fig. 2C) and HLA-DR. CX 3 CL1 was predominantly absent in human adult microglial cells, although occasionally weak and generally unconvincing immunoreactivity could be detected (Fig. 2D) . CX 3 CL1 expression levels did not differ in astrocyte cultures from patients without neurological complications or MS patients.
Strong CX 3 CR1 expression was detected in both astrocytes and microglial cells (Fig. 2E, F) . Irrelevant polyclonal antibodies showed no staining of the cultured astrocytes and microglia.
Expression of CX 3 CL1 mRNA in Cultured Human Adult Astrocytes and Microglial Cells
To investigate CX 3 CL1 mRNA expression in human glial cells, RT-PCR experiments were performed on primary astrocyte and microglial cell cultures isolated from both MS patients and patients without neurological complications. Marked CX 3 CL1 mRNA expression was detected in astrocytes cultures (Figs. 3, 4) . Moreover, under nonstimulated conditions no significant differences in the expression levels of CX 3 CL1 mRNA were detected between control and MS patients (Fig. 4) . Addition of proinflammatory cytokines such as TNF␣, IFN␥, and IL-1␤ resulted in a strong upregulation of CX 3 CL1 mRNA expression (Fig. 3) . Addition of anti-inflammatory cytokines such as IL-4, IL-10, or TGF␤1 had no effect on CX 3 CL1 mRNA expression in astrocyte cultures isolated from either MS patients or control cases (Fig. 4) . Microglia cells showed no expression of CX 3 CL1 mRNA under basal or either stimulated condition (Fig. 3) .
Chemotaxis Assay
Cellular chemotaxis in response to CX 3 CL1 stimulation was determined in order to corroborate the results showing expression of CX 3 CR1 in cultured human glial cells. Cultured human microglial cells responded with a significant migration when stimulated with 1 nM and 10 nM CX 3 CL1 in a multi-well chemotaxis assay, indicating a functional expression of CX 3 CR1 in these cells (Fig.  5) .
DISCUSSION
Emerging in vivo data suggest an important role for CX 3 CL1 in neuroinflammation and neurodegeneration. Therefore, in this study we compared the expression of CX 3 CL1 and CX 3 CR1 in human brain tissue derived from control patients without neurological complications and MS patients. The data presented here demonstrate that CX 3 CL1 is constitutively expressed in human adult CNS astrocytes in both control and MS brain tissue and under basal conditions in human adult astrocyte cell cultures. Moreover, CX 3 CR1 is expressed on astrocytes and microglial cells both in vivo and in vitro.
There has been considerable interest in determining the biological function of CX 3 CL1 in the CNS. MaciejewskiLenoir et al (18) observed different patterns of activation cascades depending on CX 3 CL1 concentrations (i.e. at low concentrations acting as a cell regulator, whereas increased concentrations suggested a proinflammatory role). Other studies have reported that the soluble form of CX 3 CL1 plays an important role in the survival and regeneration of neurons (14, 22, 27, 28) .
A major signaling consequence of CX 3 CR1 stimulation is a rapid mobilization of calcium from the extracellular pool via activation of phosphatidylinositol 3-kinase (PI3K) (29) . It has been suggested that signaling pathways diverging downstream from PI3K play multiple roles in CX 3 CR1 function, such as chemotaxis and cell survival (22, 27, 29) . Because elevation of intracellular calcium triggered by CX 3 CL1 stimulation is required for mitogen-activated protein (MAP) kinase pathway activation (29) and MAP kinase has been found to promote cell migration (30) , CX 3 CL1 might influence cell movement during tissue remodeling by activation of MAP kinase. Tissue remodeling is a major event in MS lesion development. Recently, preactive MS lesions have been described as clusters of microglial cells in a still normal appearing environment (31) . After demyelination has started due to increased inflammation, astrocytes are the most important cells not only in producing neurotrophic factors and anti-inflammatory cytokines (24) but also in the formation of an astroglial scar, leading eventually to a chronic inactive lesion. In this study we show that CX 3 CR1 is present on both microglia and astrocytes. Moreover, a functional response upon CX 3 CR1 signaling in microglial cells has been demonstrated, leading us to suggest that CX 3 CL1 might be involved in tissue remodeling in the development of MS lesions. This suggestion is strengthened by other studies in which neuronal derived CX 3 CL1 was shown to induce microglia proliferation, activation and/or migration at injured brain sites (17) . Moreover, CX 3 CL1 activated astrocytes can promote microglial cell proliferation (18) . No effect however, was shown by CX 3 CR1 activation in astrocytes on astrocyte migration (18) .
Addition of proinflammatory cytokines such as TNF␣, IFN␥, or IL-1␤ to astrocyte cultures resulted in a pronounced upregulation of CX 3 CL1 mRNA, suggesting that CX 3 CL1 presumably plays a role during acute inflammation This finding is supported by Maciejewski-Lenoir et al (18) , where CX 3 CL1 was shown to be upregulated in rat astrocytes by TNF␣ and IL-1␤. In addition, Pereira et al (21) described the upregulation of CX 3 CL1 in cocultures of astrocytes and HIV-infected macrophages wherein upregulation was dependent on cell-cell contact. In contrast, in a model of prion disease, CX 3 CL1 upregulation was detected only during chronic neurodegeneration, despite the presence of reactive astrocytes and activated microglia during active degeneration. The discrepancies were explained by environmental differences in the presence or absence of proinflammatory mediators in these different diseases. Surprisingly, results from this study demonstrate that, although upregulation of CX 3 CL1 has been described in brain inflammation, no evidence was found for expression differences of CX 3 CL1 between control patients and MS patients. This despite the fact that the proinflammatory factors inducing CX 3 CL1 mRNA expression in astrocytes are nearly absent in control brain tissues.
Our data strongly suggest that CX 3 CL1 has more general physiological functions that also occur in the absence of proinflammatory conditions. The expression of proinflammatory mediators is often down-regulated by antiinflammatory cytokines. The significance of our finding that anti-inflammatory cytokines do not affect CX 3 CL1 expression in astrocytes is presently open to speculation. An anti-inflammatory function of CX 3 CL1 has previously been proposed by Zujovic et al (32) who showed that endogenous CX 3 CL1 has the ability to control and suppress TNF␣ release from microglia. Furthermore, it has been shown that upregulation of CX 3 CL1 can block Fasmediated cell death (27) .
The presence of CX 3 CL1 on macrophages as described in this study might be explained by binding of cleaved CX 3 CL1 to the abundantly expressed CX 3 CR1 on these cells. Regulation of CX 3 CL1 cleavage is likely to have profound effects on its biological functions in the normal CNS but more importantly within the inflamed CNS. Recently, CX 3 CL1 cleavage from endothelial cells has been demonstrated to be mediated by TNF-␣-converting enzyme (TACE), a member of a family of proteins containing a disintegrin and metalloprotease domain (ADAM17). In MS lesions TNF␣ is rapidly synthesized by activated microglial cells. The identification of TACE suggests an important link between local cytokine production and the cleavage of CX 3 CL1 in activated cells (33, 34) . Furthermore, in the CNS, excitotoxicity-triggered CX 3 CL1 cleavage from neurons is dependent on a NMDA subtype of excitatory glutamate receptors and activation of metalloproteases (35) , suggesting that proteolytic cleavage from neuronal membranes and subsequent chemoattraction of reactive immune cells may represent an early event in the inflammatory response to neuronal injury (35) .
In summary, we have found no differences between CX 3 CL1 expression between control patients without neurological complications and MS patients. The biological functions of CX 3 CL1 are still uncertain; however, our data suggests a more general physiological function for CX 3 CL1.
